Tag Archives: Regeneron Pharmaceuticals

March, 2016

11 March
Regeneron and Sanofi’s RA Drug Meets Primary Endpoint in Late-Stage Trial

TARRYTOWN, N.Y. and PARIS, March 11, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA®) in improving signs and symptoms in patients with active rheumatoid arthritis …
Share

21 May
Regeneron and Sanofi’s Rheumatoid Arthritis Drug Demonstrates Positive Late-Stage Results

Regeneron Pharmaceuticals and partner Sanofi announced positive results from its late-stage study evaluating its rheumatoid arthritis candidate. The companies said that the Phase III study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function …
Share

25 March
FDA Expands Approval of Regeneron’s Eylea for Diabetic Retinopathy in Patients with Diabetic Macular Edema

The US Food and Drug Administration (FDA) has expanded approval of Regeneron’s macular degeneration drug for treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The agency’s approval of Regeneron Pharmaceuticals’ Eylea (afilibercept) injection for treatment of diabetic retinopathy (DR) in patients with DME marks the fourth approval …
Share